Spots Global Cancer Trial Database for Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Official Title: A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Study ID: NCT02078089
Conditions
Study Description
Brief Summary: This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana Univeristy Health Hospital, Indianapolis, Indiana, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Contact Details
Name: Costantine Albany, M.D.
Affiliation: Indiana University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
